CTOs on the Move

deCODE genetics

www.decode.com

 
deCODE genetics is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.decode.com
  • 1000 Winter St Ste 3100
    Waltham, MA USA '02451
  • Phone: 354.570.1900

Executives

Name Title Contact Details

Similar Companies

Iovance Biotherapeutics

Iovance Biotherapeutics is a biopharmaceutical startup based in San Carlos, California.

Nizhoni Health

At Nizhoni Health, we believe that quality of care and quality of staff go hand-in-hand. Our highly trained staff consists of qualified, experienced nurses and clinical specialists. Our nurses have worked in a variety of clinical settings including the major teaching hospitals within the metropolitan area. Nizhoni Health is a Medicare/Medicaid certified home health agency. Our enduring goal is to provide an effective alternative to inpatient hospitalization and assist clients in making the transition to the community. All clients are treated with dignity and respect.

RootPath Genomics

RootPath, Inc. is a Cambridge, MA-based early-stage biotechnology company focusing on next-generation immuno- and cell-therapy.

Barc USA

Barc USA is a New Hyde Park, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Avadim Technologies

Avadim Technologies Inc is a life sciences company that has developed a new class of life sciences solutions based on Pathogenesis Based Therapies (“PBTs”) which work to optimize the stratum corneum, integumentary functions and the associated reactive tissue. Our platform of therapies works to protect and support natural physiological functions of the outer barrier of the body, to super normalize it, supporting treatments within our three series of therapies for infection prevention, neuromuscular disorders and barrier repair. Our platform and technologies use a targeted topical delivery system, are non-toxic and are effective without the side effects of other remedy approaches. Initial acceptance in the U.S. clinical market of our first PBTs and our novel preventative approach, have shown both cost avoidance and superior effectiveness in addressing specific needs in healthcare. Avadim’s advanced therapeutic class of Pathogenesis Based Therapies is capable of unlocking pathways to address emerging gaps in global health.